Median channel shift less than the cutoff in flow cytometric crossmatch: Not to be ignored!
Sir,
The presence of donor-specific antibodies in the patient's serum is well known to be a factor in the outcome of a renal transplant recipient. There may be multiple causes of the formation of the antibodies including previous transplant, pregnancy, transfusion, or even infections. [1] Flow cytometric crossmatch (FCXM) is a sensitive, quantitative, and objective, yet cost-effective method for detection of donor-specific antibodies. [2] Although it lacks the specificity that would be offered by a Luminex single antigen bead (SAB) assay, it is a useful screening method. In a country like India where Luminex SAB assay is not yet a standard of care due to its cost implications and the majority of the transplants are with living donors, it is extremely important to identify the clues provided by FCXM results.
The standard FCXM is performed by separating the donor lymphocytes and incubating them with patient serum, along with negative and positive controls. This is followed by incubation with fluorescent-labeled anti-human immunoglobulin (Ig), which is specific for Fc part of IgG and antibodies to identify B-and T-cells. [3] The analysis includes calculating the median channel shift (MCS) of median fluorescence intensity (MFI) of the test serum vis-à-vis negative control. A cutoff is set-up by each laboratory individually which in our laboratory is set by testing number of normal sera and the cutoff point is equal to 3 standard deviation (SD). [4] The normal sera were obtained from AB-positive, nonsensitized males, which were also tested on Luminex to confirm the lack of any human leukocyte antigen (HLA) antibody. Using these sera, the cutoff was calculated to be 50 for [5]
Most of the negative FCXMs results that we get have a shift less than or equal to the negative control while the positive cases are well beyond the cutoff. We use the commercial controls as negative sera, every new lot of which is verified by testing them with Luminex SAB assay. Commercial positive controls are run as quality control measure with every test to prove the validity of the test and also meet the requirement by accreditation authorities. We rarely find cases where there is a shift, which is less than that of the cutoff. These cases are usually the ones that lie in the gray zone and an immunologist may be tempted to call them negative. We hereby report two renal transplant cases which had a shift less than the cutoff for FCXM, and which on further evaluation revealed weak donor-specific HLA antibodies (DSA) as detected by Luminex SAB assay. Both these cases were worked up in the mid of 2015.
The first case was a 49-year-old female for whom daughter was the donor and the FCXM revealed T-cell MCS of 29 and B-cell MCS of 36 as compared to the negative control [ Figure 1 ]. The complement-dependent cytotoxic (CDC) crossmatch was negative while there was panel reactive antibody (PRA) of 7% for class I. On further evaluation using Luminex SAB assay, DSA was identified against HLA-B*08, which was donor-specific. However, its MFI was only 1422 (cutoff 1000). Thus, the MCS for T-and B-cells, although less The Clinical and Laboratory Standards Institute guidelines also state that isolated T-cell positivity could be due to either non-HLA antibodies or weak Class I antibodies, which was the scenario in this case.
The second case was that of a 43-year-old patient for whom sister was the donor. The CDC crossmatch was negative while the FCXM showed an MCS of 42 beyond the negative control which was less than the cutoff for B-cells [ Figure 2 ]. The FI was only 1.8%. The FlowPRA was also negative. On performing Luminex SAB assay, DSA was identified against HLA-DRB1*14, which was again donor-specific, and had the MFI of 1519.
Both these patients underwent plasma exchange and were transplanted when their DSA MFI was <1000 and FCXM was negative. In both the cases, the posttransplant period was uneventful.
These two cases clearly show the significance of reporting/alerting the nephrologist of even a slight MCS in FCXM, which may be less than that of the set cutoff for the laboratory. Such cases warrant a further analysis using SAB assays. Most cases that are negative would have the MFI less than that of the negative control. There have been studies that have analyzed and reported the increased chances of acute humoral rejection in FCXM-negative and DSA-positive cases. [6] The negativity in the FCXM cases could have been due to the shift being less than that of the set cutoff. We are also planning to change the cutoff level to 2SD, instead of the current 3SD level, as the same would help us identify more such cases with weak HLA antibodies.
We would like to state that any shift beyond the negative control (regardless of the cutoff) in an FCXM should warrant a further evaluation, preferably using a Luminex SAB assay.
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A case of anemia: How important is peripheral blood film before transfusing?
Sir, Immediate management of a case of severe anemia presenting in CCF in the emergency room is reasonably simple with transfusion of blood or blood products. However, what is more difficult is to find out the cause of anemia and if one is scared to see such a child in emergency room, who definitely looks sick, and starts the definitive treatment, i.e. transfusion of blood/blood products, without investigating for the cause or at least preserving some pretransfusion samples for further work up, then it becomes difficult to establish the definitive diagnosis of the cause of anemia. We encountered such a case which had a reasonably simple and a common cause of anemia but had to undergo a variety of investigations just because of the fact that we did not have a pretransfusion peripheral smear examination report.
A 4½-month-old male child presented to the emergency room at 2 A.M. with complaints of fever, cough, rapid breathing, poor feeding, interrupted feeding, and excessive sweating over the forehead. On examination, the child had severe pallor, petechial and purpuric spots all over body and was in CCF and also had splenomegaly. Initial hemogram (done manually, not with cell counter) revealed severe anemia and thrombocytopenia (Hb -2.0, platelet count -27,000, total leukocyte count [TLC] -10,500, and differential leukocyte count [DLC] -N56 L40 M2 E2). Hence, possibilities kept were of sepsis or some hematological malignancy and associated severe anemia leading to congestive cardiac failure, and the child was transfused with packed red blood cell (PRBC) and platelets, following which the child improved clinically. However, a mistake done while managing this patient while wee hours was that, before transfusing, a peripheral smear was not done and neither the pretransfusion samples were preserved. The sepsis workup came out to be negative, and peripheral blood smear in post-BT samples was not suggestive of malignancy and RBC indices were normal. However, the child continued to have thrombocytopenia and even anemia did not improve significantly and required one more PRBC transfusion. Bone marrow was done which was suggestive of megaloblastic anemia. Serum Vitamin B12 levels of the infant and mother were sent which came out be very low (86 pg/ml for infant and 111 pg/ml for mother, normal range being 220-1500 pg/ml). Hence, the child was started on Vitamin B12 supplementation daily, to which he responded with an increase in reticulocyte count and hemogram normalized on day 7 of supplementation, with platelet count returning to normal (Hb-10.7, platelet count-150,000, TLC-19100, and DLC-N66 L28 M2 E2). Hence, we made a final diagnosis of Vitamin B12 deficiency with megaloblastic anemia because of deficient maternal stores and the child being exclusively breast-fed. If we had a peripheral blood film before PRBC transfusion in this child, which definitely would have been suggestive of megaloblastic anemia, we could have very well managed this child without going in for an invasive investigation like bone marrow. Hence, the emphasis here is made of preserving blood sample for a peripheral smear examination if we cannot do it before transfusing a sick child with severe anemia.
Clinical features peculiar to MA include hyperpigmentation of knuckles and terminal phalanges (observed in Asian communities), enlargement of liver and spleen (seen in up to 30%-40% cases). Petechial and other hemorrhagic manifestations have been reported in up to 25% cases. [1] The presence of bleeding with severe anemia makes them clinically indistinguishable from aplastic anemia. Cases with megaloblastic anemia may mimic acute leukemia due to the presence of hepatosplenomegaly. [2] [3] [4] Financial support and sponsorship Nil.
